VAXCYTE INC (PCVX) Stock Fundamental Analysis

NASDAQ:PCVX • US92243G1085

58.51 USD
+1.19 (+2.08%)
At close: Feb 20, 2026
58.51 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

PCVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. PCVX has a great financial health rating, but its profitability evaluates not so good. PCVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PCVX has reported negative net income.
  • PCVX had a negative operating cash flow in the past year.
  • PCVX had negative earnings in each of the past 5 years.
  • In the past 5 years PCVX always reported negative operating cash flow.
PCVX Yearly Net Income VS EBIT VS OCF VS FCFPCVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

  • PCVX has a Return On Assets of -20.72%. This is in the better half of the industry: PCVX outperforms 75.82% of its industry peers.
  • With an excellent Return On Equity value of -22.72%, PCVX belongs to the best of the industry, outperforming 81.19% of the companies in the same industry.
Industry RankSector Rank
ROA -20.72%
ROE -22.72%
ROIC N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
PCVX Yearly ROA, ROE, ROICPCVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PCVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCVX Yearly Profit, Operating, Gross MarginsPCVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for PCVX has been increased compared to 1 year ago.
  • Compared to 5 years ago, PCVX has more shares outstanding
  • There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PCVX Yearly Shares OutstandingPCVX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCVX Yearly Total Debt VS Total AssetsPCVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • PCVX has an Altman-Z score of 16.31. This indicates that PCVX is financially healthy and has little risk of bankruptcy at the moment.
  • PCVX's Altman-Z score of 16.31 is amongst the best of the industry. PCVX outperforms 87.33% of its industry peers.
  • PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.31
ROIC/WACCN/A
WACCN/A
PCVX Yearly LT Debt VS Equity VS FCFPCVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 8.83 indicates that PCVX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.83, PCVX is in the better half of the industry, outperforming 77.93% of the companies in the same industry.
  • A Quick Ratio of 8.83 indicates that PCVX has no problem at all paying its short term obligations.
  • PCVX has a better Quick ratio (8.83) than 77.93% of its industry peers.
Industry RankSector Rank
Current Ratio 8.83
Quick Ratio 8.83
PCVX Yearly Current Assets VS Current LiabilitesPCVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for PCVX have decreased by -5.09% in the last year.
EPS 1Y (TTM)-5.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PCVX will show a small growth in Earnings Per Share. The EPS will grow by 7.61% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-50.86%
EPS Next 2Y-30.61%
EPS Next 3Y-21.13%
EPS Next 5Y7.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCVX Yearly Revenue VS EstimatesPCVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
PCVX Yearly EPS VS EstimatesPCVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • PCVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCVX Price Earnings VS Forward Price EarningsPCVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCVX Per share dataPCVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • PCVX's earnings are expected to decrease with -21.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-30.61%
EPS Next 3Y-21.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PCVX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VAXCYTE INC

NASDAQ:PCVX (2/20/2026, 8:00:01 PM)

After market: 58.51 0 (0%)

58.51

+1.19 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)02-24
Inst Owners110.17%
Inst Owner Change-0.33%
Ins Owners0.65%
Ins Owner Change-24.21%
Market Cap8.25B
Revenue(TTM)N/A
Net Income(TTM)-657.20M
Analysts85.88
Price Target102.23 (74.72%)
Short Float %8.55%
Short Ratio8.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.32%
Min EPS beat(2)-20.53%
Max EPS beat(2)-2.1%
EPS beat(4)2
Avg EPS beat(4)-1.74%
Min EPS beat(4)-20.53%
Max EPS beat(4)12.92%
EPS beat(8)4
Avg EPS beat(8)-3.24%
EPS beat(12)6
Avg EPS beat(12)-1.27%
EPS beat(16)7
Avg EPS beat(16)-2.53%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.27%
PT rev (3m)0.98%
EPS NQ rev (1m)-4.1%
EPS NQ rev (3m)-6.32%
EPS NY rev (1m)-1.82%
EPS NY rev (3m)-10.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.85
P/tB 2.85
EV/EBITDA N/A
EPS(TTM)-4.83
EYN/A
EPS(NY)-6.47
Fwd EYN/A
FCF(TTM)-4.4
FCFYN/A
OCF(TTM)-3.84
OCFYN/A
SpS0
BVpS20.51
TBVpS20.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.72%
ROE -22.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1622.86%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.83
Quick Ratio 8.83
Altman-Z 16.31
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1359.67%
Cap/Depr(5y)905.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.95%
EPS Next Y-50.86%
EPS Next 2Y-30.61%
EPS Next 3Y-21.13%
EPS Next 5Y7.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-51.03%
EBIT Next 3Y-17.03%
EBIT Next 5YN/A
FCF growth 1Y-153.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-132.48%
OCF growth 3YN/A
OCF growth 5YN/A

VAXCYTE INC / PCVX FAQ

Can you provide the ChartMill fundamental rating for VAXCYTE INC?

ChartMill assigns a fundamental rating of 3 / 10 to PCVX.


What is the valuation status for PCVX stock?

ChartMill assigns a valuation rating of 0 / 10 to VAXCYTE INC (PCVX). This can be considered as Overvalued.


Can you provide the profitability details for VAXCYTE INC?

VAXCYTE INC (PCVX) has a profitability rating of 1 / 10.


Can you provide the financial health for PCVX stock?

The financial health rating of VAXCYTE INC (PCVX) is 8 / 10.


What is the expected EPS growth for VAXCYTE INC (PCVX) stock?

The Earnings per Share (EPS) of VAXCYTE INC (PCVX) is expected to decline by -50.86% in the next year.